Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 140

1.

An update of "Cost-effectiveness of rotavirus vaccination in the Netherlands: the results of a Consensus Rotavirus Vaccine model".

Tu HA, Rozenbaum MH, de Boer PT, Noort AC, Postma MJ.

BMC Infect Dis. 2013 Jan 30;13:54. doi: 10.1186/1471-2334-13-54.

2.

Cost-effectiveness of rotavirus vaccination in the Netherlands; the results of a consensus model.

Rozenbaum MH, Mangen MJ, Giaquinto C, Wilschut JC, Hak E, Postma MJ; Consensus Group on Dutch Rotavirus Vaccination (CoRoVa-Group).

BMC Public Health. 2011 Jun 10;11:462. doi: 10.1186/1471-2458-11-462.

3.

Cost effectiveness of a pentavalent rotavirus vaccine in Oman.

Al Awaidy ST, Gebremeskel BG, Al Obeidani I, Al Baqlani S, Haddadin W, O'Brien MA.

BMC Infect Dis. 2014 Jun 17;14:334. doi: 10.1186/1471-2334-14-334.

4.

An update to "The cost-effectiveness of rotavirus vaccination: comparative analyses for five European countries and transferability in Europe".

Jit M, Mangen MJ, Melliez H, Yazdanpanah Y, Bilcke J, Salo H, Edmunds WJ, Beutels P.

Vaccine. 2010 Nov 3;28(47):7457-9. doi: 10.1016/j.vaccine.2010.08.060. Epub 2010 Sep 21.

PMID:
20846529
5.

Cost-effectiveness of childhood rotavirus vaccination in Germany.

Aidelsburger P, Grabein K, Böhm K, Dietl M, Wasem J, Koch J, Ultsch B, Weidemann F, Wichmann O.

Vaccine. 2014 Apr 7;32(17):1964-74. doi: 10.1016/j.vaccine.2014.01.061. Epub 2014 Feb 20.

PMID:
24561052
6.

The cost-effectiveness of pentavalent rotavirus vaccination in England and Wales.

Atkins KE, Shim E, Carroll S, Quilici S, Galvani AP.

Vaccine. 2012 Nov 6;30(48):6766-76. doi: 10.1016/j.vaccine.2012.09.025. Epub 2012 Sep 21.

PMID:
23000223
7.

Cost-effectiveness of a pentavalent rotavirus vaccine in Japan.

Itzler R, O'Brien MA, Yamabe K, Abe M, Dhankhar P.

J Med Econ. 2013 Oct;16(10):1216-27. doi: 10.3111/13696998.2013.831869. Epub 2013 Aug 27.

PMID:
23919721
8.

Cost-Effectiveness of Monovalent Rotavirus Vaccination of Infants in Malawi: A Postintroduction Analysis Using Individual Patient-Level Costing Data.

Bar-Zeev N, Tate JE, Pecenka C, Chikafa J, Mvula H, Wachepa R, Mwansambo C, Mhango T, Chirwa G, Crampin AC, Parashar UD, Costello A, Heyderman RS, French N, Atherly D, Cunliffe NA; VACSURV Consortium.

Clin Infect Dis. 2016 May 1;62 Suppl 2:S220-8. doi: 10.1093/cid/civ1025.

9.

Economics of rotavirus gastroenteritis and vaccination in Europe: what makes sense?

Rheingans RD, Heylen J, Giaquinto C.

Pediatr Infect Dis J. 2006 Jan;25(1 Suppl):S48-55. Review.

PMID:
16397429
10.

Economic costs of rotavirus gastroenteritis and cost-effectiveness of vaccination in developing countries.

Rheingans RD, Antil L, Dreibelbis R, Podewils LJ, Bresee JS, Parashar UD.

J Infect Dis. 2009 Nov 1;200 Suppl 1:S16-27. doi: 10.1086/605026. Review.

PMID:
19817595
11.

Cost-effectiveness analysis of vaccination against rotavirus with RIX4414 in France.

Standaert B, Parez N, Tehard B, Colin X, Detournay B.

Appl Health Econ Health Policy. 2008;6(4):199-216. doi: 10.2165/00148365-200806040-00003.

PMID:
19382820
12.

Targeted rotavirus vaccination of high-risk infants; a low cost and highly cost-effective alternative to universal vaccination.

Bruijning-Verhagen P, Mangen MJ, Felderhof M, Hartwig NG, van Houten M, Winkel L, de Waal WJ, Bonten MJ.

BMC Med. 2013 Apr 26;11:112. doi: 10.1186/1741-7015-11-112.

13.

Effectiveness and cost-effectiveness of pediatric rotavirus vaccination in British Columbia: a model-based evaluation.

Fisman DN, Chan CH, Lowcock E, Naus M, Lee V.

Vaccine. 2012 Dec 14;30(52):7601-7. doi: 10.1016/j.vaccine.2012.10.034. Epub 2012 Oct 26.

PMID:
23107595
14.

Cost-effectiveness of a pentavalent human-bovine reassortant rotavirus vaccine for children ≤5 years of age in Taiwan.

Itzler RF, Chen PY, Lac C, El Khoury AC, Cook JR.

J Med Econ. 2011;14(6):748-58. doi: 10.3111/13696998.2011.614303. Epub 2011 Sep 15.

PMID:
21919673
15.

Cost-effectiveness of universal rotavirus vaccination in reducing rotavirus gastroenteritis in Ireland.

Tilson L, Jit M, Schmitz S, Walsh C, Garvey P, McKeown P, Barry M.

Vaccine. 2011 Oct 6;29(43):7463-73. doi: 10.1016/j.vaccine.2011.07.056. Epub 2011 Aug 5.

PMID:
21821085
16.

An economic analysis of rotavirus vaccination in Italy.

Giammanco MD, Coniglio MA, Pignato S, Giammanco G.

Vaccine. 2009 Jun 12;27(29):3904-11. doi: 10.1016/j.vaccine.2009.04.002. Epub 2009 Apr 24.

PMID:
19446934
17.

Socio-economic modelling of rotavirus vaccination in Castilla y Leon, Spain.

Pérez-Rubio A, Luquero FJ, Eiros Bouza JM, Castrodeza Sanz JJ, Bachiller Luque MR, de Lejarazu RO, Sánchez Porto A.

Infez Med. 2011 Sep;19(3):166-75.

18.

Cost-effectiveness of rotavirus vaccination programs in Taiwan.

Chang WC, Yen C, Chi CL, Wu FT, Huang YC, Lin JS, Huang FC, Tate JE, Wu HS, Hsiung CA.

Vaccine. 2013 Nov 4;31(46):5458-65. doi: 10.1016/j.vaccine.2013.08.103. Epub 2013 Sep 20.

PMID:
24060569
19.

[Potential cost effectiveness of a rotavirus vaccine in Chile].

Constenla D, O'Ryan M, Navarrete MS, Antil L, Rheingans RD.

Rev Med Chil. 2006 Jun;134(6):679-88. Epub 2006 Aug 14. Spanish.

20.

Dynamic modeling of cost-effectiveness of rotavirus vaccination, Kazakhstan.

Freiesleben de Blasio B, Flem E, Latipov R, Kuatbaeva A, Kristiansen IS.

Emerg Infect Dis. 2014 Jan;20(1):29-37. doi: 10.3201/eid2001.130019.

Supplemental Content

Support Center